Stockreport

Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences

Kezar Life Sciences, Inc.  (KZR) 
Last kezar life sciences, inc. earnings: 8/7 04:05 pm Check Earnings Report
PDF Transaction deepens insights into Sec61 selectivity for targeted protein degradation, supporting accelerated development of Enodia’s novel small-molecule inhibitors P [Read more]